As previously reported, BofA upgraded Edwards Lifesciences to Buy from Neutral with a price target of $105, up from $97. After having hosted the company’s CEO, CFO and Treasurer for investor meetings, the firm came away more bullish on Evoque, TAVR and “even sees asymptomatic green shoots,” says the analyst, who now sees a higher probability that Edwards can sustain double digit growth.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Bad News for Edwards Lifesciences Corp. Stock: This New Risk Has Been Added
- Edwards Lifesciences price target raised to $100 from $90 at Barclays
- Edwards Lifesciences price target raised to $86 from $64 at Deutsche Bank
- Edwards Lifesciences price target raised to $95 from $82 at RBC Capital
- Edwards Lifesciences price target raised to $86 from $81 at Canaccord